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Abstract At subtoxie concentrations, aclacinomycin is effective 
in controlling erythroid differentiation of K562, a human 
erythroleukemic ell line. To better understand early events 
implicated in this process, we have used bisindolylmaleimide 
(GF109203X), an inhibitor with a high selectivity for protein 
kinase C (PKC). Our data show that GF109203X inhibits 
aclacinomycin effects on K562, evidenced by a strong reduction 
of hemoglobinized cells and a marked decrease of mRNA rates of 
erythroid genes. To establish firmly PKC involvement, we also 
verified that aclacinomycin stimulates its rapid translocation, 
from the cytosolic to the membrane compartment. By Western 
blot analysis, we also show that after short induction times, 
PKCc~ was the most implicated. 
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brane level, acting on phospholipases which trigger specific 
cellular responses [8]. 
The aim of our investigation was to determine the role of 
PKC, if any, in the differentiating effect of ACM in K562 
cells. We show that bisindolylmaleimide, GF109203X 
(GFX), a selective inhibitor of PKC [9], markedly decreased 
ACM induction of K562 erythroid differentiation. This was 
accompanied by a decrease of erythroid gene mRNAs,  of 
GATA-1 protein, an erythroid-specific transcription factor, 
and by the inhibition of the activity of AP1, a transcription 
factor targeted by PKC. To establish firmly PKC involve- 
ment, we also verified that ACM stimulates rapid transloca- 
tion of its activity, from the cytosolic to the membrane frac- 
tion. By Western blot analysis, we showed that after short 
time courses of induction, PKCc~ isoform was mainly impli- 
cated, as soon as 5 min of induction. 
1. Introduction 
K562, a human erythroleukemic cell line, can undergo fur- 
ther differentiation in both megakaryocytic and erythroid lin- 
eages, depending on the stimulus [1]. We have previously 
shown that anthracycline antitumor drugs, at subtoxic con- 
centrations, are effective in controlling erythroid differentia- 
tion, leading to the appearance of hemoglobinized cells [2]. 
Aclacinomycin (ACM) stimulates this process by an enhance- 
ment of the transcription of specific erythroid genes, inducing 
hemoglobin production [3,4]. Nevertheless, elements about 
early events implicated in the differentiation process, espe- 
cially signal transduction pathways, remain to be elucidated. 
Among multiple known signaling mechanisms, activation of 
protein kinases C (PKC), a family of phospholipid-dependent 
serine-threonine kinases, has been shown to play a key role in 
the processes of proliferation/differentiation of a wide variety 
of malignant cells, including K562 cell line [5 7]. However, 
little is known about erythroid differentiation induced by an- 
thracyclines. These antitumor drugs, currently used in clinical 
oncology, are extremely active by provoking major damages 
of DNA. Now, they can also display their effect at the mem- 
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2. Materials and methods 
2.1. Cell culture and reagents 
Human K562 cells were grown in suspension culture in RPMI 1640 
(Life Technologies, Cergy-Pontoise, France) supplemented with 10% 
heat-inactivated fetal calf serum (Life Technologies, Cergy-Pontoise, 
France) and with 2 mM L-glutamine. Cells were maintained at 37°C in 
a humidified atmosphere containing 5% CO2. Aclacinomycin was pur- 
chased from Sigma Chemical Co. (L'Isle d'Abeau Chesnes, France) 
and the PKC inhibitor GF109203X from Calbiochem (La Jolla, CA, 
USA). Monoclonal PKC and RACK1 antibodies were obtained from 
Transduction Laboratories (Lexington, KY, USA) and anti-GATA-1 
monoclonal antibody from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). They were used according to the specifications of the 
manufacturers. 
2.2. RNA analysis 
RNA isolation was performed according to the method described 
by Chomczynski et al. [10]. 1 p_g of total RNA was reverse-transcribed 
using the Superscript Preamplification System kit (Life Technologies, 
Cergy Pontoise, France). Then, 10 gl of cDNA was diluted to 50 gl in 
Taq polymerase buffer containing 0.2 mM of each dNTP, 1 gg of each 
primer, 0.1 gl [c~-32p]dCTP (10 gCi/gl, Amersham) and 1 U of Taq 
DNA polymerase (Gibco BRL). PCR conditions involved denatura- 
tion at 94°C for 90 s, annealing for 30 s at 60°C and extension at 72°C 
for 60 s, during 15 cycles for y-globin, 20 cycles for NF-E2 and 25 
cycles for PBGD. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as an internal control. Aliquots of PCR were 
loaded on a 8% polyacrylamide g l. After drying, gels were subjected 
to autoradiography. 
Primers for mRNA evaluation were selected using the program 
PCRBASE [11] and synthesized by Eurogentec (Seraing, Belgium). 
The sequences were: 5'-GGTCCTACTATCGCCTCCCTC-3' (sense) 
and 5'-CCAGCCTCTGTCCCCTCCAGC-3' (antisense) for PBGD; 
5'-GGCAACCTGTCCTCTGCCTC-3' (sense) and 5'-GCCAGGAA- 
GCCTGCACCTCA-3' (antisense) for y-globin; 5'-ATTTGAGCCC- 
CAAGCCCCAGC-3' (sense) and 5'-CCAGCCTCTGTCCCCTC- 
CAGC-3' (antisense) for NF-E2. They generated PCR products of 
256 bp for ~/-globin, 217 bp for PBGD and 357 bp for NF-E2. 
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2.3. Western blotting 
Proteins were separated on a 10% gel by SDS-PAGE and trans- 
ferred onto nitrocellulose membrane (Amersham, Buckinghamshire, 
UK). The membrane was blocked by a 2 h incubation with 5% 
milk in 0.05% Tween 20-containing Tris-buffered saline. Immunode- 
tections were performed by incubating the membrane with the specific 
antibodies and developed with appropriate IgG-horseradish peroxi- 
dase-conjugated secondary antibodies. Development was performed 
using chemiluminescent detection reagent (Pierce, Rockford, IL, 
USA). 
2.4. Electrophoretic mobility sh(p assay 
Nuclear proteins of 4 × 106 K562 cells were prepared according to 
Schreiber et al. [12] in the presence of protease inhibitors leupeptin, 
aprotinin, o-phenanthroline, benzamidine, phenylmethylsulfonyl fluo- 
ride. In vitro binding capacity to their consensus sequence and electro- 
phoretic runs were performed as previously described by Montavani 
et al. [13]. The consensus nucleotide sequence used in these experi- 
ments was the TPA response lement (TRE) [14]. It was purchased 
from Promega (Charbonni~res, France). 
2.5. Assays for PKC activity detection 
PKC activity was evaluated in the particular and in the cytosolic 
fractions of K562 cells, according to the method described by Kikka- 
wa et al. [15]. 
3. Results 
Involvement of PKC during ACM-induced differentiation 
was first evaluated by using the specific inhibitor GF109203X. 
K562 cells were preincubated during 1 h with various concen- 
trations of GFX,  and then treated or not with ACM 20 nM. 
At  day 3, differentiation rates were assessed by measuring 
hemoglobin accumulation, after benzidine staining. GFX in- 
hibits effects of ACM in a dose-dependent manner  and at 
5 gM, the maximum non-toxic concentration, the differentia- 
t ion rate decreased from 65% to 27%, suggesting a significant 
role of PKC during this process. In order to examine the effect 
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Fig. 2. GFX downregulation of the protein level of the erythroid 
transcription factor GATA-1. Western blot analysis of GATA-I 
protein in K562 cells induced or not to differentiate by ACM for 3 
days. Untreated K562 cells (lane 1), GFX 5 gM (lane 2), ACM 20 
nM (lane 3)~ GFX 5 gM+ACM 20 nM (lane 4). 
of the inhibition of PKC on cell differentiation at the molec- 
ular level, we analyzed mRNA levels of various erythroid 
genes in presence or absence of GFX by RT-PCR.  
ACM treatment for 3 days led to a marked increase of 
mRNAs  of T-globin and porphobi l inogen deaminase 
(PBGD), which participate in hemoglobin synthesis, and of 
NF-E2, an erythroid-specific transcription factor. In the pres- 
ence of the PKC inhibitor, all these increases were suppressed, 
in spite of ACM treatment. Moreover, basal levels of these 
three erythroid markers were also reduced in uninduced cells 
only treated with GFX,  whereas that of GAPDH internal 
control did not vary during this treatment (Fig. 1). Similar 
results were obtained at the protein level by examining 
GATA-1,  another transcription factor that plays a central 
role in the regulation of erythroid differentiation [16]. Western 
blot analysis showed that GFX significantly abolished the 
GATA- I  protein increase observed after ACM stimulation 
(Fig. 2). Finally, since API transcription factor is a target 
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Fig. 1. GFX downregulation of erythroid mRNAs. RT-PCR analy- 
sis of y-globin, PBGD and NF-E2 erythroid mRNAs in K562 cells 
induced or not to differentiate by ACM for 3 days. Untreated K562 
cells (lane 1), GFX 5 gM (lane 2), ACM 20 nM (lane 3), GFX 5 
gM+ACM 20 nM (lane 4). 
Fig. 3. GFX downregulation of AP1 activity. Nuclear extracts from 
K562 cells induced or not to differentiate by ACM for 3 days were 
incubated with labeled AP1 oligodeoxynucleotide and analyzed by 
gel mobility shift assay. Untreated K562 cells (lane 1), GFX 5 gM 
(lane 2), ACM 20 nM (lane 3), GFX 5 gM+ACM 20 nM (lane 4). 
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Fig. 4. ACM-induced rapid translocation and activation of PKC. PKC activity was measured into cytosolic (open bars) and particulate 
(hatched bars) fractions of K562 cells timulated at various times with 20 nM ACM or 10 7 M PMA. Values in parentheses indicate the per- 
centage of PKC activity into cytosolic and particulate fractions. Data represent the mean + S.D. of triplicate determinations. 
for PKC-regulated changes in gene expression [17], we meas- 
ured its activity in erythroid cells by mobility shift assays, in 
the presence or not of ACM and GFX. Fig. 3 shows that 
stimulation of cells by ACM results in AP1 upregulation. 
This increase in AP1 activity was completely prevented by 
pretreatment with GFX. 
These first results strongly suggest he possible role of PKC min.  
during K562 erythroid differentiation induced by ACM. This 
was verified by measuring the translocation of total PKC 
activity, from the cytosolic to the particulate (membrane) frac- PKC ~x 
tion after treatment by the anthracycline drug. Results in Fig. 
4 show the rapid response of K562 cells to the ACM stimulus, 
since the translocation was detected within 5 30 min. At the 
basal state, PKC activity was 47% of the total activity (0.201 
pmol/~tg protein) in the particulate fraction. During the first 
30 min of ACM treatment, a progressive increase of this PKC 
activity was found (61% after 5 rain and 77% after 30 min). 
However, this increase in PKC activity was smaller than that 
observed with PMA, a reference activator of PKC. 
In order to identify specific PKC isotypes implicated, we PKC 
carried out immunoblot analysis of both particulate and cy- 
tosolic fractions after short time induction by ACM. Stripping 
and reprobing blots permitted us to analyze the same extracts 
with various specific antibodies. As shown in Fig. 5, PKC PKC 0 
isotype analysis demonstrated that undifferentiated K562 cells 
express or, 13I, 13II and e in both fractions. In our conditions 
was only present in the cytosolic fraction and a was no detect- PKC 
able (a whole rat brain lysate was used as a positive control, 
but no band appeared with K562 extracts). Induction with 
ACM led to a rapid activation of c~ isoform, which was trans- 
located from the cytosolic to the particulate fraction within 
the first 30 min of treatment. No change was observed with 
the other isoforms tested. Finally, RACK1, a specific receptor 
for activated PKC [18], which is present at low levels in the 
cytosol, was strongly increased in the membrane fraction as 
soon as 5 min after ACM induction. 
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Fig. 5. Western blot analysis of PKC isoforms. Redistribution of 
PKC isoforms was evaluated after 5 and 30 min of treatment with 
20 nM ACM. Cytosolic and membrane subfractions were prepared 
as described in Section 2. A representative of three separate xperi- 
ments is reported. 
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4. Discussion 
In this study we demonstrated for the first time that one 
mechanism by which the anthracycline antitumor drug ACM 
transduces the signal leading to erythroid differentiation was 
PKC-dependent. There was a strong reduction of erythroid 
differentiation by the GFX inhibitor, confirmed by the inhib- 
ition of various erythroid markers and of the binding of the 
ubiquitous transcription factor AP1, which is a well-known 
target for PKC [17]. Moreover, we observed a marked and 
rapid membrane translocation of the activity of total PKC 
after ACM treatment. This response was attributed to the c~ 
isotype and may implicate the anchoring protein RACK1, the 
level of which in the membrane fraction was also increased 
after ACM stimulation. 
These data are in agreement with other studies that dem- 
onstrate a mechanism of action originating at the cell mem- 
brane level for anthracycline antitumor drugs. Indeed, we pre- 
viously showed that covalent coupling of an anthracycline to 
a solid phase support, used to focus the drug action to the cell 
membrane, induces the appearance of differentiated cells with- 
out penetrating into the cells [19]. In addition, anthracycline 
antibiotics can be incorporated into phospholipid bilayer [20], 
where they interfere with membrane-associated enzymatic ac- 
tivities, leading to specific phospholipase C (PLC) activation 
[21]. In this case, the subsequent liberation of diacylglycerol 
could explain one of the mechanisms of action of ACM on 
PKC. According to this, the xanthogenate compound D609, a 
specific inhibitor of phosphatidylcholine-phospholipase C, 
was able to inhibit ACM-induced differentiation in a dose- 
dependent manner (unpublished results from our laboratory). 
The role of PKC during the differentiation of leukemia cells 
is one of the most studied areas in hematology [22]. PKC~, 
whose role in normal and cancer cells is controversial, has 
been shown to contribute to cell differentiation in various 
systems, including the murine erythroleukemia Friend cell 
line. In this case, a temporal relationship between PKCc~ iso- 
form localization to the nucleus and commitment to differ- 
entiation was established, indicating its important role in the 
signal transduction pathway to gene expression [23]. It should 
nevertheless be noticed that other isotypes can play a role 
during this process, depending on the differentiating agents 
used and with respect to the cell lines, on the differential 
modulation and subcellular distribution of PKC isotypes 
[24 27]. 
The next events leading to the appearance of the erythroid 
phenotype of K562 cells after anthracyclines treatment remain 
to be elucidated. Studies are ongoing to establish the relation- 
ship between transduction pathways, more particularly PKC, 
and activation of specific transcription factors like GATA-1, 
which when phosphorylated exhibits an increase in its binding 
activity to erythroid promoters [28]. 
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